Anastrozole and Clascoterone Interaction: Monitor | Peptide Database

First-line pharmacotherapy for ED of various etiologies. Demonstrated efficacy across a broad range of populations including patients with diabetes, spinal cord injury, post-radical prostatectomy, and psychogenic ED. Effective in approximately 70-85% of men with ED. Rapid onset and predictable duration make sildenafil well-suited for planned sexual activity. The shorter therapeutic window provides a defined period of enhanced erectile response without prolonged pharmacological effect. FDA-approved as Revatio (20mg TID) for PAH (WHO Group 1) to improve exercise capacity and delay clinical worsening. Reduces mean pulmonary artery pressure, pulmonary vascular resistance, and improves 6-minute walk distance. Evidence from controlled trials demonstrates that sildenafil reduces the frequency and severity of Raynaud's attacks by enhancing digital blood flow through NO-cGMP pathway augmentation. Used off-label in refractory cases. Acute and chronic PDE5 inhibition with sildenafil improves flow-mediated dilation and endothelial-dependent vasodilation across various cardiovascular risk populations. Sildenafil has been studied for the prevention and treatment of high-altitude pulmonary edema (HAPE) by reducing exaggerated hypoxic pulmonary vasoconstriction. Used off-label by climbers and military personnel at extreme altitudes. Used off-label in neonatal ICUs for persistent pulmonary hypertension of the newborn (PPHN) when inhaled nitric oxide is unavailable or insufficient. Evidence supports its use as an adjunct therapy. Enhanced vasodilation may increase blood flow to working muscles. Some evidence suggests improved exercise performance at altitude via reduced pulmonary artery pressure. Effects at sea level are less well-established.

Join others researching RU-58841 — share findings, ask questions, and learn from real experiences RU-58841 is a non-steroidal anti-androgen originally developed by Roussel Uclaf (later Hoechst Marion Roussel) in the 1970s-80s for topical treatment of androgen-dependent conditions including acne and androgenetic alopecia. It works by competitively binding to androgen receptors at the hair follicle, blocking the effects of dihydrotestosterone (DHT) locally without significantly reducing systemic androgen levels. Development was abandoned after Phase II clinical trials, and the compound was never submitted for regulatory approval. Despite this, RU-58841 has developed a substantial following in the hair loss community, where users source it as a raw research chemical and prepare their own topical solutions. Its extremely short systemic half-life means that even if absorbed through the skin, it is rapidly metabolized, limiting systemic anti-androgenic effects. However, the lack of completed clinical trials means its long-term safety profile remains unknown. RU-58841 functions as a competitive antagonist of the androgen receptor (AR). When applied topically to the scalp, it penetrates the skin and binds directly to androgen receptors in dermal papilla cells of hair follicles, preventing dihydrotestosterone (DHT) and testosterone from activating those receptors. This is fundamentally different from 5-alpha reductase inhibitors like finasteride, which reduce DHT production systemically. RU-58841 does not lower DHT or testosterone levels at all; it simply blocks their action at the receptor level in the tissue where it is applied. The compound has a very high binding affinity for the androgen receptor but an extremely short systemic half-life of roughly one hour due to rapid hydrolysis of its amide bond in the bloodstream. This pharmacokinetic profile is intentional: it confines the anti-androgenic activity to the scalp while minimizing the risk of systemic side effects such as sexual dysfunction or hormonal disruption. Animal studies in hamster flank organ and stumptail macaque models demonstrated significant local anti-androgenic effects, including hair regrowth and inhibition of androgen-dependent sebaceous gland activity, without measurable systemic anti-androgenic effects at therapeutic topical doses.